Pfizer Inc.
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Last updated:
Abstract:
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR.RTM., SYNFLORIX.RTM. and/or PREVNAR 13.RTM.. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
Status:
Application
Type:
Utility
Filling date:
6 Mar 2021
Issue date:
1 Jul 2021